Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review
| العنوان: | Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review |
|---|---|
| المؤلفون: | Andrej Janez, Manfredi Rizzo, Djordje S. Popovic, Anca Pantea Stoian, Nikolaos Papanas, Ali A. Rizvi |
| المساهمون: | Popovic D.S., Papanas N., Pantea Stoian A., Rizvi A.A., Janez A., Rizzo M. |
| المصدر: | Diabetes Therapy |
| بيانات النشر: | Springer Science and Business Media LLC, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), 1 receptor agonists, Sodium-glucose co-transporter , Endocrinology, Diabetes and Metabolism, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), COVID-19, Dipeptidyl peptidase , Review, Type 2 diabetes, Sodium-glucose co-transporter 2 inhibitors, Glucagon-like peptide 1 receptor agonists, Diabetes mellitus, Pandemic, Internal Medicine, medicine, 2 diabetes, Intensive care medicine, Antidiabetic agents, 4 inhibitors, Glucagon-like peptide , business.industry, COVID-19, medicine.disease, Systemic inflammatory response syndrome, Shock (circulatory), Dipeptidyl peptidase 4 inhibitors, medicine.symptom, business, 2 inhibitors, Type |
| الوصف: | Severe acute respiratory syndrome coronavirus2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). The latter is a pandemic that has the potential of developing into a severe illness manifesting as systemic inflammatory response syndrome, acute respiratory distress syndrome, multi-organ involvement and shock. In addition, advanced age and male sex and certain underlying health conditions, like type2 diabetes mellitus (T2DM), predispose to a higher risk of greater COVID-19 severity and mortality. This calls for an urgent identification of antidiabetic agents associated with more favourable COVID-19 outcomes among patients with T2DM, as well as recognition of their potential underlying mechanisms. It is crucial that individuals with T2DM be kept under very stringent glycaemic control in order to avoid developing various cardiovascular, renal and metabolic complications associated with more severe forms of COVID-19 that lead to increased mortality. The use of novel antidiabetic agents dipeptidyl peptidase4 inhibitors (DPP4i), sodium-glucose co-transporter2 inhibitors (SGLT2i) and glucagon-like peptide1 receptor agonists (GLP-1RAs) in subjects with T2DM may have beneficial effects on COVID-19 outcomes. However, relevant studies either show inconsistent results (DPP4i) or are still too few (SGLT2i and GLP-1RAs). Further research is therefore needed to assess the impact of these agents on COVID-19 outcomes. |
| تدمد: | 1869-6961 1869-6953 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5299514d22a08c56c16759e41199dfebTest https://doi.org/10.1007/s13300-021-01170-3Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....5299514d22a08c56c16759e41199dfeb |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 18696961 18696953 |
|---|